Phase II California Cancer Consortium trial of gemcitabine–eribulin combination (GE) in cisplatin ineligible patients (pts) with metastatic urothelial carcinoma (mUC): tolerability and toxicity report (NCI-9653; 1UM1CA186717-01, NO1-CM-2011-00038). (February 2017) - Sadeghi, S.; Groshen, S.; Parikh, R.; Mortazavi, A.; Dorff, T.; Hoimes, C.; Pal, S.; Levine, E.; Doyle, L.; Quinn, D.; Newman, E.; Lara, P.